Clinical Trials – A Cautionary Tale

clinical trilas fullerton neurology center
Clinical Trials Tales

This was big news several months ago. A phase I drug Clinical Trials in France resulted in a death in 1 healthy volunteer and neurological deficits in 3 others. The details were published in the New England Journal of Medicine, November 3, 2016. The drug was considered to be an analgesic, anti-inflammatory, and possibly effective for neuropathic pain. It targeted the endocannabinoid system. The manufacturer was Bial, a pharmaceutical company based in Portugal.

 

The medication seemed safe in animal testing, and this led to a phase I trial, which is designed to test safety and not efficacy in humans. Bial went ahead with the study even though other drug companies had tested molecules that were similar and seemed ineffective.

 

This trial started in January 2016, with 8 volunteers. Two received placebo and six a 50 mg dose of the medication. All 6 of the treated patients were hospitalized with adverse effects, starting on the fifth day of drug administration. Nevertheless, the researchers continued to treat the other patients.

 

The toxicity was neurological. MRI showed hyperintense lesions, mainly in the brainstem and hippocampal areas.

 

Lessons are obvious. Researchers should know when to stop. The dosing should have been staggered rather than all patients being treated at the same time.

 

Volunteers in phase I trials have no possibility of benefit from the trial, unlike patients in phase II and phase III trials. They do so largely because they are being compensated. Several years ago The New Yorker published an article explaining that there is a group of young men for whom clinical trials are their livelihood. Phase I trials are essential in development of medications. They are ethical as long as there is true informed consent and appropriate safeguards are in place.

 

See Neurology Today, December 8, 2016.

 

Visit pur Center’s website for more information.

 

How Often Is Syncope Caused By Pulmonary Embolism?

According to a study in the October 20, 2016, issue of the New England Journal of Medicine, surprisingly so, specifically 1 out of every 6 patients admitted for first-time syncope. It was found in 24% of patients who presented with syncope when no other cause was found and even 13% among those who had another potential cause.

 

Keep in mind that in the study of 560 patients most were older than 75 years. They were screened with a D-dimer blood test, and the diagnosis was confirmed with a CT angiogram of the chest or V/Q scanning.

 

Patients were identified at 11 hospitals in Italy over a 4-year period. Lead author is Paolo Prandoni. Comments by several experts varied from great skepticism to a feeling of being validated for similarly held beliefs. If the results can be validated, they will likely change clinical practice for elderly patients with syncope. Benefits of anticoagulation would outweigh risks of CT angiography.

 

For more information, please visit our website.

 

Fullerton, Neurology, Headache, Treatment, Center
Fullerton Neurology and Headache Center